A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2001
11/08/2001	WO2001083554A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083547A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083530A1 Porphyromonas gingivalis recombinant proteins and truncations
11/08/2001	WO2001083529A2 Immunoadhesin for the prevention of rhinovirus infection
11/08/2001	WO2001083525A2 Modified peptides, comprising an fc domain, as therapeutic agents
11/08/2001	WO2001083524A2 Rna metabolism proteins
11/08/2001	WO2001083520A2 Polyacid glycopeptide derivatives
11/08/2001	WO2001083512A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	WO2001083510A1 29 human secreted proteins
11/08/2001	WO2001083501A1 Anti-viral pyrimidine nucleoside analogues
11/08/2001	WO2001083496A1 Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents
11/08/2001	WO2001083492A1 Improved beta-lactam antibiotics
11/08/2001	WO2001083486A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001	WO2001083476A1 Chromenylmethyl pyrimidinediamines as antibacterial agents
11/08/2001	WO2001083474A1 Pyrimidinyl methyl indole derivatives with antibacterial activity
11/08/2001	WO2001083425A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	WO2001083385A2 Devices and method for production of traceable immunizing drinking water, other liquids and gas
11/08/2001	WO2001082975A2 Membrane-permeant peptide complexes for medical imaging
11/08/2001	WO2001082971A2 Cyclodextrin containing glycopeptide antibiotic compositions
11/08/2001	WO2001082968A1 Cell proliferation inhibitors
11/08/2001	WO2001082966A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
11/08/2001	WO2001082965A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	WO2001082964A1 Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
11/08/2001	WO2001082963A2 Method of identifying and producing antigen peptides and use thereof as vaccines
11/08/2001	WO2001082962A2 Immunizing against hiv infection
11/08/2001	WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001	WO2001082944A1 Methods and compositions for impairing multiplication of hiv-1
11/08/2001	WO2001082941A1 Composition for treatment of b-type hepatitis and liver cirrhosis
11/08/2001	WO2001082930A1 Pyrazole antimicrobial agents
11/08/2001	WO2001082927A1 Antibiral compositions containing phorbol derivatives as the main active ingredient
11/08/2001	WO2001082922A1 Oral compositions comprising polyphenol herbal extracts
11/08/2001	WO2001082905A1 Pharmaceutical formulation comprising carrier beads coated with a layer of valaciclovir
11/08/2001	WO2001082897A2 Liposome drug delivery
11/08/2001	WO2001082788A2 Compounds and methods for the treatment and prevention of bacterial infection
11/08/2001	WO2001060349A3 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001036630A3 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
11/08/2001	WO2001034190A3 Live bacterial vaccines against escherichia coli o157:h7
11/08/2001	WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001	WO2001030383A3 Medicament in order to induce tolerance
11/08/2001	WO2001026680A3 Activation of antigen-specific t cells by virus/antigen-treated dendritic cells
11/08/2001	WO2001023414A3 Immunologically significant herpes simplex virus antigens
11/08/2001	WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001	WO2001007468A3 Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
11/08/2001	WO2001002551A3 Virus like particles, preparation and use in screening and functional genomics
11/08/2001	WO2000076556A9 High dose radionuclide complexes for bone marrow suppression
11/08/2001	WO2000053775A9 Prevention and treatment of viral infections
11/08/2001	WO2000053745A9 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
11/08/2001	US20010039669 Polynucleotide comprising caprine arthritis encephalitis virus (CAEV) viral genome renders nonpathogenic to a primate a resulting retroviral particle produced via gene expression, generating immune response against HIV-1
11/08/2001	US20010039350 Suitable for prophylaxis of diseases involving interleukin-1 beta such as septic shock, leukemia, hepatits, muscular degeneration, HIV infections, or degenerative joint diseases
11/08/2001	US20010039343 Pesticides, fungicides, herbicides, insecticides, microbiocdes, drugs
11/08/2001	US20010039342 Chemical intermediate for stavudine
11/08/2001	US20010039333 Reacting with methanesulfonic acid; neutralization; crystallization
11/08/2001	US20010039281 No drug resistance; intravenous
11/08/2001	US20010039276 Phenethyl-thiourea compounds and use
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039273 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
11/08/2001	US20010039038 Novel glucosaminidase
11/08/2001	US20010039026 Assay method
11/08/2001	US20010038843 Immunogenic polypeptide comprising a self Immunoglobin E (IgE) portion and a non-self IgE portion, to induce an anti-self IgE response in a mammal; treating diseases such as allergies
11/08/2001	US20010038838 Empiric treatment of infections potentially caused by drug resistance streptococcus pneumoniae in a human patient comprising the oral administration of a formulation comprising amoxycillin and potassium clavulanate
11/08/2001	US20010038824 Aerothricins antifungal cyclic peptides
11/08/2001	CA2750984A1 Porphyromonas gingivalis recombinant proteins and truncations
11/08/2001	CA2726789A1 Cyclodextrin containing glycopeptide antibiotic compositions
11/08/2001	CA2433897A1 Pharmaceutical formulation comprising carrier beads coated with a layer of valaciclovir
11/08/2001	CA2420287A1 Anthrax specific antibodies
11/08/2001	CA2418748A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	CA2416725A1 Immunizing against hiv infection
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2409689A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	CA2409219A1 Cellular regulators of infectious agents and methods of use
11/08/2001	CA2408011A1 Splice-region antisense composition and method
11/08/2001	CA2407956A1 Modified peptides as therapeutic agents
11/08/2001	CA2407797A1 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	CA2407785A1 Use of .alpha.-msh and epo for preventing or treating ischemic conditions
11/08/2001	CA2407746A1 Proteases
11/08/2001	CA2407700A1 Compositions and methods for inducing activation of dendritic cells
11/08/2001	CA2407603A1 Porphyromonas gingivalis recombinant proteins and truncations
11/08/2001	CA2407597A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001	CA2407443A1 Compounds and methods for the treatment and prevention of bacterial infection
11/08/2001	CA2407435A1 Rna metabolism proteins
11/08/2001	CA2407426A1 Immunoadhesin for the prevention of rhinovirus infection
11/08/2001	CA2407399A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/08/2001	CA2407303A1 Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
11/08/2001	CA2407292A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
11/08/2001	CA2406746A1 Methods and compositions for impairing multiplication of hiv-1
11/08/2001	CA2405614A1 Chromenylmethyl pyrimidinediamines as antibacterial agents
11/08/2001	CA2405611A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	CA2405607A1 Pyrimidinyl methyl indole derivatives with antibacterial activity
11/08/2001	CA2405363A1 Epitope synchronization in antigen presenting cells
11/08/2001	CA2403901A1 29 human secreted proteins
11/07/2001	EP1152243A1 DIagnosis of Sjögren's syndrome, systemic lupus erythematosis, and scleroderma via detection of anti-retroviral antibodies
11/07/2001	EP1152057A1 Antibody binding to human airway trypsin-like enzyme and utilization thereof
11/07/2001	EP1152009A1 Novel nucleosides and oligonucleotide analogues
11/07/2001	EP1152007A1 Ether type lipid a1-carboxylic acid analogues
11/07/2001	EP1152002A1 Pyrrole derivatives and cell death inhibitors
11/07/2001	EP1151995A1 Process for the preparation of the mesylate salt trihydrate of 1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidin-1-YL)-1-Propanol
11/07/2001	EP1151131A1 Process for the preparation of pseudomonic acid a antibiotic by microbiological method

1 ... 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 ... 1798